PPARA and metabolic dysfunction-associated steatohepatitis: Lanifibranor (Fig. 2), 20 4-[1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol-2-yl]butanoic acid, is under clinical trial's investigations under number NCT03008070.52 Inflammatory, metabolic, and hepatic fibrotic pathways are modulated by the panperoxisome proliferator activated receptor (PPAR) agonist lanifibranor in the pathogenesis of non-alcoholic steatohepatitis (NASH).72,73